ALPS Group Inc Dossier - Source-backed chat

ALPS Group Inc

ALPSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.40Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $66.2M

Enterprise Value $66.4M

Shares Outstanding 166.4M diluted

Next Earnings Date31 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alps Group Inc (NASDAQ: ALPS) is a newly public, integrated biotechnology platform headquartered in Malaysia that operates a unique 'bench-to-bedside' model. The company leverages commercial revenues from its aesthetic treatments, molecular diagnostics, and wellness centers to fund its pre-clinical R&D pipeline (including autologous NK cell therapies and mRNA technologies). While the recent MS ISO 15189:2022 clinical accreditation for its subsidiary MyGenome's Whole Genome Sequencing (WGS) services marks a significant technical milestone, the company faces substantial near-term headwinds. These include a Nasdaq minimum bid price deficiency notice (with a compliance deadline of November 11, 2026), a limited cash runway ($643,252 in cash against $779,231 in debt), and ongoing operating losses (-$2.64 million net loss over the last 12 months). Investors should maintain a Hold stance until the company demonstrates a clear path to regulatory compliance, stabilized cash flows, and commercial scale.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to regain compliance with Nasdaq's minimum bid price rule and is delisted to the OTC market, severely limiting liquidity. Commercial revenues stagnate, and the limited cash runway forces highly dilutive equity financing to sustain pre-clinical R&D operations.

Base CaseCentral scenario

The company successfully leverages its newly accredited WGS capabilities to secure clinical partnerships across Southeast Asia, driving commercial revenue growth. It manages to regain Nasdaq compliance through organic price recovery or a reverse stock split before November 2026. R&D expenses remain controlled, and commercial operations continue to offset pre-clinical pipeline burn.

Bull CaseUpside scenario

Successful commercialization of its autologous NK cell pipeline and expansion of its patient-derived organoid (PDO) program across Southeast Asia, driving significant revenue growth and establishing market leadership in precision medicine.

Scenarios reflect our research view at the research date.

Key Investment Merits

Unique integrated business model that uses immediate commercial healthcare and aesthetic revenues to fund long-term biotechnology R&D.
MyGenome subsidiary holds MS ISO 15189:2022 clinical accreditation for Whole Genome Sequencing, establishing a strong technical moat in Southeast Asia.
Strategic geographic positioning in the rapidly growing Southeast Asian precision medicine and wellness market.

Key Investment Risks

Nasdaq listing deficiency risk, with the stock trading below the $1.00 minimum bid price threshold.
Severely constrained liquidity and cash runway, with only $643,252 in cash and cash equivalents against ongoing operating losses.
High execution and regulatory risk associated with bringing pre-clinical cell therapies and mRNA pipelines to commercialization.

Thesis Invalidation Triggers

Delisting from the Nasdaq Stock Market to the OTC market due to failure to cure the bid price deficiency.
A material drop in commercial aesthetic and wellness revenues, which would cut off the primary funding source for R&D.
Inability to secure additional capital or strategic partnerships, leading to a halt in pre-clinical pipeline development.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.